BioLife Solutions, Inc. $BLFS Shares Acquired by Summit Creek Advisors LLC

Summit Creek Advisors LLC grew its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 24.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 238,802 shares of the medical equipment provider’s stock after acquiring an additional 46,541 shares during the period. Summit Creek Advisors LLC’s holdings in BioLife Solutions were worth $5,774,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of BLFS. Hantz Financial Services Inc. grew its stake in shares of BioLife Solutions by 54.1% in the third quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock worth $48,000 after acquiring an additional 659 shares in the last quarter. Quarry LP grew its stake in shares of BioLife Solutions by 50.9% in the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after acquiring an additional 713 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of BioLife Solutions by 82.0% in the third quarter. PNC Financial Services Group Inc. now owns 4,425 shares of the medical equipment provider’s stock worth $113,000 after acquiring an additional 1,994 shares in the last quarter. Strs Ohio acquired a new position in shares of BioLife Solutions in the first quarter worth $153,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of BioLife Solutions by 547.9% in the second quarter. Tower Research Capital LLC TRC now owns 7,133 shares of the medical equipment provider’s stock worth $154,000 after acquiring an additional 6,032 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on BLFS. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Monday, April 20th. Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 12th. Finally, Wall Street Zen upgraded shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, BioLife Solutions has a consensus rating of “Hold” and a consensus price target of $32.00.

Insider Activity

In other news, insider Karen A. Foster sold 96,923 shares of BioLife Solutions stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $20.15, for a total transaction of $1,952,998.45. Following the completion of the sale, the insider directly owned 113,742 shares of the company’s stock, valued at approximately $2,291,901.30. The trade was a 46.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 99,641 shares of company stock worth $2,009,000. 2.20% of the stock is currently owned by insiders.

BioLife Solutions Trading Up 4.1%

BioLife Solutions stock opened at $24.00 on Thursday. The stock has a market cap of $1.17 billion, a P/E ratio of -299.96 and a beta of 1.97. The company has a fifty day simple moving average of $20.46 and a 200-day simple moving average of $22.96. BioLife Solutions, Inc. has a 12-month low of $17.86 and a 12-month high of $29.62.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.03. The business had revenue of $27.50 million during the quarter, compared to analysts’ expectations of $25.66 million. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. As a group, sell-side analysts forecast that BioLife Solutions, Inc. will post 0.09 earnings per share for the current fiscal year.

BioLife Solutions Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.